7:00AM BioDelivery Services Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence (BDSI) 3.33 : Co announced positive preliminary results from its Phase 1 study assessing the pharmacokinetics of a BEMA Buprenorphine/Naloxone formulation. BDSI is seeking to develop and commercialize a high dose formulation of buprenorphine combined with naloxone for the treatment of opioid dependence. Results of the study demonstrated the ability of the BEMA formulation to meet the key pharmacokinetic goal of delivering plasma concentrations of buprenorphine in the range needed to treat opioid dependence while minimizing the exposure of naloxone."If the results from this pivotal study are positive, we could be in a position to submit a New Drug Application for BEMA Buprenorphine/Naloxone in the second half of 2012." stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.
Market Data 
Markets 
AI
